share_log

Baird Initiates Coverage On Bright Minds Biosciences With Outperform Rating, Announces Price Target of $75

Benzinga ·  Nov 26 05:21  · Ratings

Baird analyst Joel Beatty initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $75.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment